Results 21 to 30 of about 126,909 (281)
Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM
Journal of Education, Health and SportBackground: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka +3 more
doaj +2 more sources
TWO CLASSES OF MYOSIN INHIBITORS, BLEBBISTATIN AND MAVACAMTEN, STABILIZE β-CARDIAC MYOSIN IN DIFFERENT STRUCTURAL AND FUNCTIONAL STATES [PDF]
bioRxiv, 2020 In addition to a conventional relaxed state, a fraction of myosins in the cardiac muscle exists in a newly-discovered low-energy consuming super-relaxed (SRX) state, which is kept as a reserve pool that may be engaged under sustained increased cardiac ...
Sampath K Gollapudi +7 more
semanticscholar +2 more sources
American Journal of Cardiovascular DrugsHypertrophic cardiomyopathy (HCM) affects as many as 1 in 200 people in the adult population globally. Patients may present with exertional dyspnea, presyncope or syncope, atrial and ventricular arrhythmias, heart failure, and even sudden cardiac death ...
Jan K Kalinski +9 more
semanticscholar +3 more sources
Scientific ReportsHypertrophic cardiomyopathy (HCM) remains the most common cardiomyopathy in humans and cats with few preclinical pharmacologic interventional studies. Small-molecule sarcomere inhibitors are promising novel therapeutics for the management of obstructive ...
Victor N. Rivas +12 more
doaj +2 more sources
An engineered cardiac reporter cell line identifies human embryonic stem cell-derived myocardial precursors. [PDF]
, 2011 Unlike some organs, the heart is unable to repair itself after injury. Human embryonic stem cells (hESCs) grow and divide indefinitely while maintaining the potential to develop into many tissues of the body.
Bernstein, Harold S +7 more
core +16 more sources
Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal. [PDF]
Future CardiolHypertrophic cardiomyopathy is a heterogenous genetic condition caused by myocyte disarray with varying degrees of interstitial fibrosis. Traditional management strategies focused on symptom mitigation and sudden cardiac death prevention among high-risk ...
Keen S, Desai MY.
europepmc +2 more sources
Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
Frontiers in Physiology, 2022 Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana +3 more
doaj +1 more source
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]
Drug Des Devel TherHou L, Lin B, Ji X, Huang A.
europepmc +3 more sources
Therapeutic Advances in Chronic Disease, 2022 Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterised by unexplained left ventricular hypertrophy. Left ventricular outflow tract obstruction is an integral component of the disease, often resulting in significant symptoms, but ...
Susan Mathai, Lynne Williams
doaj +1 more source